A proven history of innovation – Zilver^® PTX^®

Our mission with Zilver PTX—and with every product we make at Cook Medical—is to try to improve patients’ lives. We have released extensive data around Zilver PTX, and this device continues to show benefits across a wide spectrum of patients.

Only Zilver PTX combines the antiproliferative drug paclitaxel with polymer-free drug delivery and vessel support to demonstrate superior 5-year results against percutaneous transluminal angioplasty (PTA) and Zilver bare-metal stents.

Additional resources

• Zilver PTX product page
• Zilver PTX brochure
• Thumbwheel animation
• Zilver PTX: Transparency, data, and patient safety (Update)
• The Zilver PTX Single-Arm Study
• Zilver PTX results for diabetic and nondiabetic patients
• Short-term paclitaxel delivery in the SFA has been proven beneficial
• Zilver PTX vs. Eluvia drug and stent technology
• Load and exposure time for paclitaxel-coated devices in the SFA
• Watch Dr. Charles Bailey discuss Zilver PTX global data overview

References

1. Dake MD, Ansel GM, Jaff MR, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation. 2016;133(15):1472-83.